Advertisement
Loading...

Foundation Medicine, Inc.

FMINASDAQ
Healthcare
Biotechnology
$137.00
$0.00(0.00%)
U.S. Market is Open • 13:35
Advertisement

Foundation Medicine, Inc. Fundamental Analysis

Foundation Medicine, Inc. (FMI) shows weak financial fundamentals with a PE ratio of -34.26, profit margin of -93.83%, and ROE of -1.46%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-2.15
Current Ratio1.86

Areas of Concern

ROE-1.46%
Operating Margin-1.05%
We analyze FMI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -264.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-264.7/100

We analyze FMI's fundamental strength across five key dimensions:

Efficiency Score

Weak

FMI struggles to generate sufficient returns from assets.

ROA > 10%
-84.89%

Valuation Score

Excellent

FMI trades at attractive valuation levels.

PE < 25
-34.26
PEG Ratio < 2
-2.15

Growth Score

Weak

FMI faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

FMI shows balanced financial health with some risks.

Debt/Equity < 1
1.89
Current Ratio > 1
1.86

Profitability Score

Weak

FMI struggles to sustain strong margins.

ROE > 15%
-146.02%
Net Margin ≥ 15%
-93.83%
Positive Free Cash Flow
N/A

Key Financial Metrics

Is FMI Expensive or Cheap?

P/E Ratio

FMI trades at -34.26 times earnings. This suggests potential undervaluation.

-34.26

PEG Ratio

When adjusting for growth, FMI's PEG of -2.15 indicates potential undervaluation.

-2.15

Price to Book

The market values Foundation Medicine, Inc. at 155.21 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

155.21

EV/EBITDA

Enterprise value stands at -0.07 times EBITDA. This is generally considered low.

-0.07

How Well Does FMI Make Money?

Net Profit Margin

For every $100 in sales, Foundation Medicine, Inc. keeps $-93.83 as profit after all expenses.

-93.83%

Operating Margin

Core operations generate -1.05 in profit for every $100 in revenue, before interest and taxes.

-1.05%

ROE

Management delivers $-1.46 in profit for every $100 of shareholder equity.

-1.46%

ROA

Foundation Medicine, Inc. generates $-84.89 in profit for every $100 in assets, demonstrating efficient asset deployment.

-84.89%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-3.81 in free cash annually.

$-3.81

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-34.26

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-2.15

vs 25 benchmark

P/B Ratio

Price to book value ratio

155.21

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.89

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.86

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.46

vs 25 benchmark

ROA

Return on assets percentage

-0.85

vs 25 benchmark

ROCE

Return on capital employed

-1.57

vs 25 benchmark

How FMI Stacks Against Its Sector Peers

MetricFMI ValueSector AveragePerformance
P/E Ratio-34.2629.35 Better (Cheaper)
ROE-146.02%705.00% Weak
Net Margin-93.83%-53441.00% (disorted) Weak
Debt/Equity1.890.39 Weak (High Leverage)
Current Ratio1.864.01 Neutral
ROA-84.89%-19815.00% (disorted) Weak

FMI outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Foundation Medicine, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ